Drugs

In a Win for Consumers, AG Becerra Announces $70 Million Pay-For-Delay Settlement

California’s Attorney General Xavier Becerra today announced four settlements totaling nearly $70 million in payments against pharmaceutical companies for participating in harmful “pay-for-delay” deals that keep lower-priced generic medications off the market for longer, reducing competition and arbitrarily keeping life-saving medications more expensive for consumers.  According to the AG, this is the largest settlement of […] Read More

On 100th Day, Governor Newsom Announces New Partner on Prescription Drug Purchasing Pool

On his 100th day in office, Governor Gavin Newsom announced a partnership with Los Angeles County on prescription drug purchasing, putting together the power of the country’s biggest state and county for the biggest discounts and lower prices needed for medications. The State of California and Los Angeles County buy drugs for similar purposes and […] Read More

Legislation to Deter ‘Pay for Delay’ Agreements Passes Key Judiciary Committee

A first-of-its-kind state legislation to prevent “pay-for-delay” pharmaceutical company pricing practices passed the Assembly Judiciary Committee today with bipartisan support. The California bill seeks to prevent brand name drug manufacturers offering patent settlements to pay generic companies to delay the introduction of lower-price medication to the market. The bill, AB 824 authored by Assemblymember Jim […] Read More

New Bill to Lower Drug Prices Targets Practice of “Pay-for-Delay”

Consumer advocates cheered the introduction of a bill to address the outrageous pharmaceutical company practice of “pay for delay,” where drug manufacturers offer patent settlements to pay generic companies to delay the introduction of lower-price medication to the market. According to an FTC study, “these anti-competitive deals cost consumers and taxpayers $3.5 billion in higher drug costs […] Read More

Court Halts Big Pharma Efforts to Stop California’s Landmark Prescription Drug Price Transparency Law

In a win for consumers, the U.S. District Court, Eastern District of California today dismissed a lawsuit brought by the Pharmaceutical Research and Manufacturers of America (PhRMA) to halt California’s landmark drug price transparency law, SB 17, authored by Senator Ed Hernandez in 2017. Last year, PhRMA filed this lawsuit alleging the law as unconstitutional […] Read More

President Trump’s 136 Question Marks on Prescription Drug Prices

After multiple reschedules, President Donald Trump gave a speech last week on prescription drug prices, unveiling a plan to address the issue that was underwhelming–several noted that the plan had few specific actions, and in fact literally had 136 question marks. While President Trump prioritized lowering prescription drug prices during his campaign, while in office […] Read More

Website for New Prescription Drug Price Transparency Law (SB 17) Now Live

Implementation of the ground-breaking California law to provide transparency and notice of prescription drug price increases is moving ahead full steam. The law will take effect on January 1, 2018, but the the Office of Statewide Health Planning and Development (OSHPD) has already made live the registry for public and private purchasers to receive 60-day notice […] Read More

Setting National Policy, CA Governor Brown Signs SB 17 on Prescription Drug Price Transparency

This morning, California Governor Jerry Brown signed SB 17 by Senator Ed Hernandez, nationally influential prescription drug price legislation, at a rare signing ceremony at the State Capitol. The new law will require prescription drug companies to provide advance notice and explanation for any price hike of more than 16% over two years. Despite a heavy […] Read More

California Poised to Set National Policy on Prescription Drug Prices

Earlier this week, SB 17, by Senator Ed Hernandez, passed off the Senate floor on a concurrence vote, putting California only a Governor’s signature away from enacting nationally impactful prescription drug price reform. After receiving overwhelming bipartisan support heading out of the State Assembly, the State Senate also affirmed that addressing drug prices increases is a […] Read More